Ann: European Patent to be Granted for Cholesterol-Lowering Drug, page-5

I've loosely followed NYR too. Briefly bought in and went back out about a month ago because I just didn't have the amount of capital that I tend to want to commit to a play like this. But I like the story.

I believe the Phase I trials are happening later this year if I'm not mistaken. One is for TBI so similar to one of the other companies we both hold. The anti-cholesterol play seems very promising but I believe Merck has a drug that has appeared just as promising which is ahead clinically and has validated results in humans (NYR is pre clinical only). However it is a large space so may be room for more than one player.

I believe NYR is aiming to be snapped up post-Phase I which could mean less time until good shareholder returns.

I'll continue to follow NYR. It looks promising and undervalued but not sure how differentiated the assets are or if there is a moat.